| Antithrombin III concentrates--are they clinically useful? | |
| | |
MedLine Citation:
|
PMID: 7667814 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Treatment with AT III concentrates is a good example for the discrepancy between the optimistic expectations based on theoretical considerations or animal experiments and the result of clinical studies. 15 years after the introduction into clinical practice, a benefit for patients treated with AT III concentrates has not been proven. In hereditary antithrombin III deficiency, randomized clinical trials are completely lacking and only few and small sized randomized studies were performed in patients with acquired AT III deficiency. In none of these trials, a significant clinical benefit with regard to reduction of morbidity or mortality was detectable. Based on the published data, one can state that AT III concentrates may be beneficial in some special clinical situations in patients with hereditary antithrombin III deficiency (such as delivery, acute serious thromboembolic complications and postoperative thromboprophylaxis). In acquired AT III deficiency, there is no proven indication for the use of AT III concentrates. |
| | |
Authors:
|
K Lechner; P A Kyrle |
Related Documents
:
|
7284544 - Clinical trials:randomization before consent. 15495114 - Antibiotic regimens for suspected early neonatal sepsis. 15495034 - Thrombolysis for acute deep vein thrombosis. 7846414 - Considerations in choice of a clinical endpoint for aids clinical trials. terry beirn c... 9708654 - Influence of the preoperative signal-averaged electrocardiogram on left ventricular fun... 12045904 - Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 73 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 1995 Mar |
Date Detail:
|
Created Date: 1995-10-11 Completed Date: 1995-10-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 340-8 Citation Subset: IM |
Affiliation:
|
Department of Medicine I, University of Vienna, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antithrombin III
/
isolation & purification,
pharmacokinetics,
therapeutic use* Antithrombin III Deficiency Asparaginase / adverse effects Clinical Trials as Topic Female Genetic Predisposition to Disease Humans Infant, Newborn Kidney Diseases / metabolism, therapy Liver Diseases / metabolism, therapy Postoperative Complications / prevention & control Pregnancy Pregnancy Complications, Hematologic / therapy Randomized Controlled Trials as Topic Safety Shock, Septic / therapy Thromboembolism / genetics, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
9000-94-6/Antithrombin III; EC 3.5.1.1/Asparaginase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Growth hormone in adults. An elixir of youth?
Next Document: Fibrin polymerization defect in HIV-infected patients--evidence for a critical role of albumin in th...